Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Cash from Financing Activities (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Cash from Financing Activities for 4 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 7251.04% to $44.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $43.5 million, a 2780.7% increase, with the full-year FY2025 number at $43.5 million, up 2780.7% from a year prior.
  • Cash from Financing Activities was $44.7 million for Q4 2025 at Spruce Biosciences, up from -$402000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $50.5 million in Q1 2023 to a low of -$625000.0 in Q4 2024.
  • A 4-year average of $5.7 million and a median of -$382500.0 in 2024 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 57519.32% in 2023; the steepest drop was 1633.33% in 2023.
  • Spruce Biosciences' Cash from Financing Activities stood at $36000.0 in 2022, then crashed by 1633.33% to -$552000.0 in 2023, then fell by 13.22% to -$625000.0 in 2024, then surged by 7251.04% to $44.7 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Cash from Financing Activities are $44.7 million (Q4 2025), -$402000.0 (Q3 2025), and -$400000.0 (Q2 2025).